Amedeo Smart

Free Medical Literature Service

 

Amedeo

Neoplasms of the CNS
  Free Subscription

Articles published in
J Neuropathol Exp Neurol
    August 2026
  1. RAQUIB AR, Schwartz SN, Siddiqi SH, Varma H, et al
    An open-source application for automated quantification of Ki-67 proliferative index in meningiomas.
    J Neuropathol Exp Neurol. 2026 Aug 21:nlag083. doi: 10.1093.
    >> Share

  2. YELDIR N, Sargolzaeimoghaddam M, Sargolzaeimoghaddam M, Cakir A, et al
    Proliferation patterns across meningioma locations: A WHO grade-based analysis.
    J Neuropathol Exp Neurol. 2026 Aug 13:nlag090. doi: 10.1093.
    >> Share

    July 2026
  3. DE MENDONCA FERNANDES GM, Wu KC, Palmer J, Carrau R, et al
    NICO Myriad Automated Preservation System improves meningioma sample quality for molecular pathology assays.
    J Neuropathol Exp Neurol. 2026 Jul 20:nlag030. doi: 10.1093.
    >> Share

    June 2026
  4. FIOCCHI A, Rushing EJ, Brandt S, Kloepper J, et al
    Novel YWHAE-NTRK3 fusion in a pediatric glioma.
    J Neuropathol Exp Neurol. 2026 Jun 26:nlag065. doi: 10.1093.
    >> Share

  5. WEN Y, He Y, Li J, Zhou H, et al
    Comprehensive identification of FoxO signaling as a promising prognostic and immunotherapeutic biomarker in glioma.
    J Neuropathol Exp Neurol. 2026 Jun 2:nlag059. doi: 10.1093.
    >> Share

    May 2026
  6. SUN Y, Jia Y, Bu X, Chen Y, et al
    Leucine-rich pentatricopeptide repeat-containing protein silencing transcriptionally regulated by GATA-binding protein 3 has an anti-glioma effect by regulating glycolysis and ferroptosis by mediating N6-methyladenosine modification of protocadherin-7
    J Neuropathol Exp Neurol. 2026 May 4:nlag043. doi: 10.1093.
    >> Share

  7. HIGA N, Akahane T, Yokoyama S, Yonezawa H, et al
    Molecular and clinical prognostic factors in isocitrate dehydrogenase-mutant astrocytomas: Insights into biomarker-driven stratification.
    J Neuropathol Exp Neurol. 2026;85:455-463.
    >> Share

    March 2026
  8. KAHR J, Diaz-Peregrino R, Sandalcioglu IE, John P, et al
    RagC and Map4K3 deficiency in high-grade gliomas drives proliferation and modulates mTORC1-dependent cellular functions.
    J Neuropathol Exp Neurol. 2026 Mar 22:nlag010. doi: 10.1093.
    >> Share

  9. SPYRETOS C, Pardo Ladino JM, Andersen Blomstrand H, Nyman P, et al
    Quantification of Ki-67 labeling index in pediatric brain tumor immunohistochemistry images.
    J Neuropathol Exp Neurol. 2026 Mar 10:nlaf163. doi: 10.1093.
    >> Share

  10. EBNER BA, Ida CM, Kollmeyer TM, Jenkins RB, et al
    Association of CDKN2A/B and MTAP deletions in adult-type diffuse gliomas.
    J Neuropathol Exp Neurol. 2026 Mar 9:nlag007. doi: 10.1093.
    >> Share

  11. COTY-FATTAL Z, Smith H, McCord M, Mejia-Bautista M, et al
    Rapid assessment of MGMT promoter methylation status by droplet digital polymerase chain reaction on intraoperative smear preparation: A proof-of-concept study.
    J Neuropathol Exp Neurol. 2026;85:280-284.
    >> Share

    February 2026
  12. NISHIDA N, Hata Y
    Sudden unexpected death associated with previously undiagnosed gliomas: A mechanism-based interpretation of three autopsy cases.
    J Neuropathol Exp Neurol. 2026 Feb 14:nlag006. doi: 10.1093.
    >> Share

  13. GRAY MT, Cayrol R, May A, Skaugen JM, et al
    Gliomas with succinate dehydrogenase deficiency: A case series and brief review of the literature of oncometabolite-driven gliomagenesis.
    J Neuropathol Exp Neurol. 2026 Feb 4:nlag004. doi: 10.1093.
    >> Share

    January 2026
  14. YUAN J, Liu H, Wen J, Zhao Z, et al
    Cardiotrophin-like cytokine factor 1 regulated by Sry-related HMG-box transcription factor 9 promotes malignant behavior and immune evasion of glioblastoma multiforme.
    J Neuropathol Exp Neurol. 2026 Jan 19:nlaf161. doi: 10.1093.
    >> Share

  15. VOYLES C, Bellizzi AM, Lopes Abath Neto O
    Survival analysis of brain-invasive otherwise benign meningiomas in a single-institution cohort.
    J Neuropathol Exp Neurol. 2026 Jan 12:nlaf157. doi: 10.1093.
    >> Share

    December 2025
  16. FUKUOKA K, Irikura T, Kanemura Y, Hirato J, et al
    Intratumoral heterogeneity of MYC status and methylation subtyping in group 3 medulloblastoma: A case report.
    J Neuropathol Exp Neurol. 2025 Dec 23:nlaf153. doi: 10.1093.
    >> Share

  17. MAFFICINI A, Pigato F, Miele E, Patrizi S, et al
    Fumarate hydratase-mutant glioma with giant-cell histology, MSH6 mutation, and hypermutation.
    J Neuropathol Exp Neurol. 2025 Dec 9:nlaf142. doi: 10.1093.
    >> Share

  18. CHIANG WY, Li X, Tanaka R, Chiang J, et al
    Activated signaling pathways and metabolic processes in disseminating myxoid glioneuronal tumors.
    J Neuropathol Exp Neurol. 2025;84:1106-1112.
    >> Share

    November 2025
  19. BELAKHOUA S, Lopez G, Dubey S, Rai S, et al
    RECQL4 alterations in gliomas and nerve sheath tumors: Expression patterns and therapeutic implications.
    J Neuropathol Exp Neurol. 2025 Nov 29:nlaf129. doi: 10.1093.
    >> Share

  20. BROECHNER A, Maier AD, Mirian C, Sahm F, et al
    Analysis of anatomical location, mitoses, and Ki-67 in 2608 meningiomas.
    J Neuropathol Exp Neurol. 2025 Nov 20:nlaf131. doi: 10.1093.
    >> Share

  21. WELCH RL, Fluss RS, Yokoda RT, Himes BT, et al
    Primary sporadic intracranial DICER1 mutant sarcoma with SSTR2 positivity in an adult patient mimicking anaplastic meningioma.
    J Neuropathol Exp Neurol. 2025 Nov 11:nlaf053. doi: 10.1093.
    >> Share

  22. WENG M, Zhu X
    FOXM1/CENPI axis regulation of proline and arginine metabolism in glioblastoma cells.
    J Neuropathol Exp Neurol. 2025 Nov 4:nlaf121. doi: 10.1093.
    >> Share

    October 2025
  23. MANDARA MT, Giglia G, Benedetti G, Falzone C, et al
    Tumor-associated macrophages in feline meningiomas: Exploring their prognostic significance.
    J Neuropathol Exp Neurol. 2025 Oct 21:nlaf119. doi: 10.1093.
    >> Share

  24. MURAYI R, El-Abtah M, Ejikeme T, Xiao T, et al
    Validation of an immunohistochemistry-based molecular group stratification of intracranial meningiomas.
    J Neuropathol Exp Neurol. 2025 Oct 15:nlaf120. doi: 10.1093.
    >> Share

    September 2025
  25. GUO Y, Liu H, Gao Z, Zhou Z, et al
    Mitochondrial dysfunction and its impact on pyroptosis and ferroptosis cross talk in glioma cells.
    J Neuropathol Exp Neurol. 2025 Sep 17:nlaf099. doi: 10.1093.
    >> Share

  26. VOONG V, Beccari S, Hashemi E, Kriener B, et al
    3D spatial sampling to quantify morphologic heterogeneity in isocitrate dehydrogenase-wildtype glioblastoma.
    J Neuropathol Exp Neurol. 2025 Sep 3:nlaf101. doi: 10.1093.
    >> Share

    August 2025
  27. ZHANG Z, Guo X, Qi T, Wang C, et al
    METTL14/IGF2BP2-mediated m6A modification of PD-L1 promotes proliferation, metastasis, and immune escape in high-grade gliomas.
    J Neuropathol Exp Neurol. 2025 Aug 11:nlaf090. doi: 10.1093.
    >> Share

    July 2025
  28. HAO Z, Han Y, Bo Y, Cao L, et al
    Knocking down RFWD3 suppresses the growth and migration of glioblastoma cells by blocking G2/M cycle progression.
    J Neuropathol Exp Neurol. 2025 Jul 23:nlaf087. doi: 10.1093.
    >> Share

  29. LIECHTY B, Kim S, Dobri G, Schwartz TH, et al
    SSTR2 expression in neoplastic and normal anterior pituitary is impacted by age, sex, and hormonal status.
    J Neuropathol Exp Neurol. 2025;84:626-633.
    >> Share

  30. HARPER SD, Perryman T, Dudley LA, Prabhu AS, et al
    Molecular characterization of benign intracranial glioependymal and arachnoid cysts suggest heterogeneous mechanisms of action.
    J Neuropathol Exp Neurol. 2025;84:617-625.
    >> Share

  31. SIDDIQ Z, Gilani A, Ung TH, Kleinschmidt-DeMasters BK, et al
    Isocitrate dehydrogenase-mutant astrocytoma in persons aged 55 years and older: Survival differences versus the young.
    J Neuropathol Exp Neurol. 2025;84:611-616.
    >> Share

    June 2025
  32. LOCHNER RH, Powell SZ, Fung KM, Zhang YJ, et al
    FGFR1 fusions in genomically and epigenetically bona fide glioblastoma, IDH-wildtype.
    J Neuropathol Exp Neurol. 2025 Jun 12:nlaf068. doi: 10.1093.
    >> Share

  33. TERRY M, Reis G, Pekmezci M, Phillips JJ, et al
    PAS+/PASD- intracytoplasmic glycogen is not specific for clear cell meningioma.
    J Neuropathol Exp Neurol. 2025 Jun 6:nlaf065. doi: 10.1093.
    >> Share

    May 2025
  34. TOLLEFSEN SE, Meta R, Solheim O, Mjones P, et al
    Merlin immunoreactivity fails to predict neurofibromatosis type 2 mutations in human meningiomas.
    J Neuropathol Exp Neurol. 2025 May 30:nlaf058. doi: 10.1093.
    >> Share

  35. TAUZIEDE-ESPARIAT A, Rousseau A, Basset L, Saffroy R, et al
    A comparison of CDKN2A status in gliomas using different techniques: The loss of p16 as a surrogate marker.
    J Neuropathol Exp Neurol. 2025 May 30:nlaf062. doi: 10.1093.
    >> Share

  36. FURUTA T, Miyoshi H, Moritsubo M, Nakajima R, et al
    Biological role and clinicopathological significance of leucine-rich alpha-2 glycoprotein 1 in the glioblastoma microenvironment.
    J Neuropathol Exp Neurol. 2025 May 9:nlaf049. doi: 10.1093.
    >> Share

  37. ROBINS SM, Rosenblatt M, Bruce JN, Canoll P, et al
    Solitary fibrous tumor in the pineal region: A series of 5 cases and literature review.
    J Neuropathol Exp Neurol. 2025;84:379-390.
    >> Share

    April 2025
  38. COOK DJ, Decker PA, Hardcastle JJ, Kollmeyer TM, et al
    EGFR transcript variants: Potential diagnostic biomarker for glioblastoma, IDH-wildtype?
    J Neuropathol Exp Neurol. 2025 Apr 25:nlaf041. doi: 10.1093.
    >> Share

  39. UGWUOWO U, Faust B, Tang H, DiStasio M, et al
    Adequate capture of spatial heterogeneity of Ki-67 proliferative index in meningiomas requires multiple tissue sections.
    J Neuropathol Exp Neurol. 2025 Apr 21:nlaf043. doi: 10.1093.
    >> Share

  40. DONO A, Pichardo-Rojas D, Mendoza Mora L, Pichardo-Rojas PS, et al
    MTAP immunohistochemistry as a surrogate marker of CDKN2A loss in brain tumors: A meta-analysis and literature review.
    J Neuropathol Exp Neurol. 2025 Apr 18:nlaf033. doi: 10.1093.
    >> Share

  41. LI Y, Shen X, Zhang J, Xian X, et al
    Adult diffuse IDH-wildtype lower-grade gliomas with PDGFRA gain/amplification should be upgraded as glioblastoma.
    J Neuropathol Exp Neurol. 2025 Apr 16:nlaf039. doi: 10.1093.
    >> Share

  42. NGUYEN P, Yokoda RT, Hossain Q, Bederson JB, et al
    Solitary fibrous tumor-meningioma collision tumor with 18 years of follow-up.
    J Neuropathol Exp Neurol. 2025 Apr 11:nlaf037. doi: 10.1093.
    >> Share

    February 2025
  43. MORENO-TORRES B, Manzano-Benito I, Cantero D, Romo A, et al
    Integrating molecular analyses with the 2021 WHO classification of adult pilocytic astrocytomas.
    J Neuropathol Exp Neurol. 2025;84:255-263.
    >> Share

    December 2024
  44. CHEN A, Hart SL, Lannon M, Hawkins C, et al
    Meningiomas in Rubinstein-Taybi syndrome: A case report and comprehensive review.
    J Neuropathol Exp Neurol. 2024 Dec 31:nlae135. doi: 10.1093.
    >> Share

  45. VIZCAINO MA, Giannini C, Vaubel RA, Nguyen AT, et al
    Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytoma.
    J Neuropathol Exp Neurol. 2024;83:1003-1009.
    >> Share

    November 2024
  46. GUO Y, Li Y, Su P, Yan M, et al
    Tumor microtubes: A new potential therapeutic target for high-grade gliomas.
    J Neuropathol Exp Neurol. 2024 Nov 19:nlae119. doi: 10.1093.
    >> Share

    October 2024
  47. SHEKARIAN T, Ritz MF, Hogan S, Martins TA, et al
    Multidimensional analysis of matched primary and recurrent glioblastoma identifies contributors to tumor recurrence influencing time to relapse.
    J Neuropathol Exp Neurol. 2024 Oct 18:nlae108. doi: 10.1093.
    >> Share

  48. CECCHI R, Guptil D, Haslett N, Hristov A, et al
    Primary CNS histiocytic sarcoma: Two case reports highlighting a novel MIGA2::BRAF gene fusion and genome-wide DNA methylation profiling results.
    J Neuropathol Exp Neurol. 2024;83:882-886.
    >> Share

    September 2024
  49. OHARA K, Al Assaad M, McNulty SN, Alnajar H, et al
    Detection of rare and novel gene fusions in patients with diffuse glioma: An institutional retrospective study.
    J Neuropathol Exp Neurol. 2024 Sep 28:nlae105. doi: 10.1093.
    >> Share

  50. REIMANN RR, Gramatzki D, Bink A, Hench J, et al
    Long survival in a patient with fumarate hydratase mutation-associated glioma.
    J Neuropathol Exp Neurol. 2024 Sep 16:nlae100. doi: 10.1093.
    >> Share

  51. KLEINSCHMIDT-DEMASTERS BK
    Mixed pituitary adenoma/pituitary neuroendocrine tumor-gangliocytoma: Immunohistochemical insights.
    J Neuropathol Exp Neurol. 2024;83:708-721.
    >> Share

  52. FENG Y, Wong PJC, Fu M, Kong Y, et al
    The comprehensive morphological and molecular characteristics of lipoastrocytoma: A case report.
    J Neuropathol Exp Neurol. 2024;83:785-790.
    >> Share

    August 2024
  53. WANG C, Han H, Cheng F, Wang H, et al
    Clinical significance and potential mechanism of AEBP1 in glioblastoma.
    J Neuropathol Exp Neurol. 2024 Aug 27:nlae091. doi: 10.1093.
    >> Share

  54. TIAN S, Xie G, Zhang H, Zuo F, et al
    A heritable form of SMARCE1-related meningiomas with clinical implications.
    J Neuropathol Exp Neurol. 2024 Aug 19:nlae080. doi: 10.1093.
    >> Share

  55. MORRIS M, Ararat K, Cutshall H, Gokden M, et al
    SMARCA4-deficient central nervous system metastases: A case series and systematic review.
    J Neuropathol Exp Neurol. 2024;83:638-654.
    >> Share

  56. ABOUBAKR O, Senova S, Kauv P, Castel D, et al
    A non-midline unclassified glioneuronal tumor with H3K27M mutation enlarging the spectrum of CNS tumors H3K27ME3-altered.
    J Neuropathol Exp Neurol. 2024;83:701-705.
    >> Share

    July 2024
  57. TANAKA Y, Natsumeda M, Ohashi M, Saito R, et al
    Primary spinal cord gliomas: Pathologic features associated with prognosis.
    J Neuropathol Exp Neurol. 2024 Jul 29:nlae084. doi: 10.1093.
    >> Share

  58. ALTURKUSTANI M, Walker AD, Castaneda EA, Cotter JA, et al
    Utility of OLIG2 immunostaining in pediatric brain tumors with embryonal morphology.
    J Neuropathol Exp Neurol. 2024 Jul 27:nlae082. doi: 10.1093.
    >> Share

  59. KANATHANAVANICH M, Koga S, Stone SL, Roth J, et al
    CTDSP2::GLI1 fusion in glioblastoma: A diagnostic challenge through tumor heterogeneity.
    J Neuropathol Exp Neurol. 2024 Jul 9:nlae073. doi: 10.1093.
    >> Share

  60. LE MK, Tran NQV, Nguyen PT, Nguyen TA, et al
    Comprehensive analysis of distinct circadian clock subtypes of adult diffuse glioma and their associations with clinicopathological, genetic, and epigenetic profiles.
    J Neuropathol Exp Neurol. 2024 Jul 4:nlae055. doi: 10.1093.
    >> Share

  61. FENG K, Ye G, Wang H, Li S, et al
    Research on the mechanism of TWSG1 in the malignant progression of glioma cells and tumor-associated macrophage infiltration.
    J Neuropathol Exp Neurol. 2024 Jul 1:nlae067. doi: 10.1093.
    >> Share

    June 2024
  62. KISELJAK-VASSILIADES K, Lipe K, Turin CG, Fishbein L, et al
    E-cadherin expression and gene expression profiles in corticotroph pituitary neuroendocrine tumor subtypes.
    J Neuropathol Exp Neurol. 2024;83:586-595.
    >> Share

  63. PARKER M, Kazemi F, Krishnakumar A, Horowitz MA, et al
    Availability and utilization of molecular testing for primary central nervous system tumors among US hospitals.
    J Neuropathol Exp Neurol. 2024;83:579-585.
    >> Share

  64. ZSCHERNACK V, Thomas C, Schaub C, Kristiansen G, et al
    FH-mutant glioma displaying the epigenetic signature of IDH-mutant astrocytomas.
    J Neuropathol Exp Neurol. 2024 Jun 14:nlae064. doi: 10.1093.
    >> Share

  65. LORETO PALACIO P, Pan X, Jones D, Otero JJ, et al
    Exploring a distinct FGFR2::DLG5 rearrangement in a low-grade neuroepithelial tumor: A case report and mini-review of protein fusions in brain tumors.
    J Neuropathol Exp Neurol. 2024 Jun 4:nlae040. doi: 10.1093.
    >> Share

    May 2024
  66. SHIBAHARA I, Nakashima T, Toyoda M, Inukai M, et al
    Evolving driver mutations in adult-onset SHH-medulloblastoma originated from radiological cerebellar abnormality.
    J Neuropathol Exp Neurol. 2024 May 29:nlae051. doi: 10.1093.
    >> Share

  67. VIZCAINO MA, Giannini C, Lalich D, Nael A, et al
    Ganglioglioma with anaplastic/high-grade transformation: Histopathologic, molecular, and epigenetic characterization of 3 cases.
    J Neuropathol Exp Neurol. 2024;83:416-424.
    >> Share

    April 2024
  68. MACRAE CB, Grieco KC, Solomon IH
    Diagnostic yield of postmortem brain examination following premortem brain biopsy for neoplastic and nonneoplastic disease.
    J Neuropathol Exp Neurol. 2024;83:331-337.
    >> Share

  69. WILCOCK DM, Goold E, Zuromski LM, Davidson C, et al
    EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization.
    J Neuropathol Exp Neurol. 2024 Apr 11:nlae028. doi: 10.1093.
    >> Share

    March 2024
  70. KALTER JA, Yang RA, Toland A, Milla S, et al
    IDH-mutant astrocytoma arising from a demyelinating plaque in a child with X-linked adrenoleukodystrophy.
    J Neuropathol Exp Neurol. 2024;83:289-292.
    >> Share

  71. NEWMAN J, Leelatian N, Liang J
    Characterization of pediatric non-hematopoietic tumor metastases to the central nervous system: A single institution review.
    J Neuropathol Exp Neurol. 2024;83:268-275.
    >> Share

  72. DONEV K, Sundararajan V, Johnson D, Balan J, et al
    Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?
    J Neuropathol Exp Neurol. 2024 Mar 6:nlae018. doi: 10.1093.
    >> Share

    February 2024
  73. QI P, Yao QL, Lao IW, Ren M, et al
    A custom next-generation sequencing panel for 1p/19q codeletion and mutational analysis in gliomas.
    J Neuropathol Exp Neurol. 2024 Feb 26:nlae011. doi: 10.1093.
    >> Share

  74. KRAUSE KA, Woods JK, Golby AJ, Lee EQ, et al
    Progestin-associated meningiomatosis with unusual schwannoma-like morphology.
    J Neuropathol Exp Neurol. 2024 Feb 1:nlae008. doi: 10.1093.
    >> Share

    January 2024
  75. XI S, Huang Q, Zeng J
    A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.
    J Neuropathol Exp Neurol. 2024;83:125-130.
    >> Share

  76. FENG Y, Xu H, Hu X, Zhang J, et al
    Heterogenous driving genetic events contribute to the dissemination of choroid plexus papilloma.
    J Neuropathol Exp Neurol. 2024;83:131-135.
    >> Share

  77. MARIET C, Grill J, Ajlil Y, Castel D, et al
    "Hemispheric pilocytic astrocytoma" revisited: A comprehensive clinicopathological and molecular series emphasizing their overlap with other glioneuronal tumors.
    J Neuropathol Exp Neurol. 2024;83:115-124.
    >> Share

  78. ABOUBAKR O, Metais A, Doz F, Saffroy R, et al
    LEF-1 immunohistochemistry, a better diagnostic biomarker than beta-catenin for medulloblastoma, WNT-activated subtyping.
    J Neuropathol Exp Neurol. 2024 Jan 17:nlad104. doi: 10.1093.
    >> Share

  79. GUBBIOTTI MA, Weinberg JS, Weathers SP, Dasgupta P, et al
    An incidental finding of a high-grade glioma with pleomorphic and pseudopapillary features (HPAP) with PBRM1 mutation.
    J Neuropathol Exp Neurol. 2024 Jan 2:nlad114. doi: 10.1093.
    >> Share

    December 2023
  80. ROBINSON LJ, Goold E, Potter S, Quigley EP, et al
    A pleomorphic xanthoastrocytoma highlighting the morphological heterogeneity of this uncommon tumor.
    J Neuropathol Exp Neurol. 2023;83:61-64.
    >> Share

  81. GUNDOGDU F, Babaoglu B, Soylemezoglu F
    Reliability assessment of methylthioadenosine phosphorylase immunohistochemistry as a surrogate biomarker for CDKN2A homozygous deletion in adult-type IDH-mutant diffuse gliomas.
    J Neuropathol Exp Neurol. 2023 Dec 18:nlad109. doi: 10.1093.
    >> Share

    November 2023
  82. GESTRICH C, Grieco K, Lidov HG, Baird LC, et al
    H3K27-altered diffuse midline gliomas with MAPK pathway alterations: Prognostic and therapeutic implications.
    J Neuropathol Exp Neurol. 2023 Nov 30:nlad103. doi: 10.1093.
    >> Share

  83. HUA Y, Youens KE, Castro E, Wang D, et al
    Autopsy findings in a 6-month-old infant with rhabdoid tumor predisposition syndrome 1: Case report with literature review.
    J Neuropathol Exp Neurol. 2023;82:1040-1043.
    >> Share

  84. WHITE B, Filo J, Orrego-Gonzalez E, Schwartz SN, et al
    Synchronous contralateral low-grade oligodendroglioma and high-grade IDH-mutant astrocytoma.
    J Neuropathol Exp Neurol. 2023;82:1048-1050.
    >> Share

  85. NUECHTERLEIN N, Shelbourn A, Cimino PJ
    Whole gain of chromosome 19, not co-gain of chromosomes 19 and 20, characterizes a class of glioblastomas with more favorable outcomes.
    J Neuropathol Exp Neurol. 2023 Nov 14:nlad092. doi: 10.1093.
    >> Share

  86. BLUM N, Mirian C, Maier AD, Mathiesen TI, et al
    Translocator protein (TSPO) expression in neoplastic cells and tumor-associated macrophages in meningiomas.
    J Neuropathol Exp Neurol. 2023 Nov 11:nlad093. doi: 10.1093.
    >> Share

    October 2023
  87. NAZEM A, Lavezo J, Abdullaev Z, Aldape K, et al
    Diffuse hemispheric glioma with H3-3B G34R mutation: Expanding the spectrum of histone H3 genes in diffuse hemispheric glioma, H3 G34-mutant.
    J Neuropathol Exp Neurol. 2023 Oct 25:nlad089. doi: 10.1093.
    >> Share

  88. ABOUBAKR O, Metais A, Hasty L, Saffroy R, et al
    Brainstem oligodendroglioma, IDH-mutant, and 1P/19Q-codeleted: A potential diagnostic pitfall.
    J Neuropathol Exp Neurol. 2023;82:958-962.
    >> Share

  89. CAO C, Zhang L, Sorensen MD, Reifenberger G, et al
    D-2-hydroxyglutarate regulates human brain vascular endothelial cell proliferation and barrier function.
    J Neuropathol Exp Neurol. 2023;82:921-933.
    >> Share

  90. SHELBOURN A, Nuechterlein N, Parada CA, Eaton J, et al
    Validating MCM2 as a clinically relevant surrogate immunohistochemical marker for an aggressive meningioma molecular subtype.
    J Neuropathol Exp Neurol. 2023 Oct 13:nlad082. doi: 10.1093.
    >> Share

  91. KOLEILAT A, Kumar V, Al Hmada Y, Milosevic D, et al
    Concurrent TERT promoter C228T and C250T mutations in diffuse gliomas: Rare occurrence of intratumoral heterogeneity.
    J Neuropathol Exp Neurol. 2023 Oct 9:nlad081. doi: 10.1093.
    >> Share

    September 2023
  92. XU E, Stone SL, Zhong Y, Golenberg N, et al
    A novel ARIH1::BRAF fusion in a glioma.
    J Neuropathol Exp Neurol. 2023 Sep 23:nlad074. doi: 10.1093.
    >> Share

  93. ZHANG Y, Huang H, Liu P, Xie Y, et al
    NFYB increases chemosensitivity in glioblastoma by promoting HDAC5-mediated transcriptional inhibition of SHMT2.
    J Neuropathol Exp Neurol. 2023 Sep 23:nlad073. doi: 10.1093.
    >> Share

  94. YOKODA RT, Cobb WS, Yong RL, Crary JF, et al
    CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.
    J Neuropathol Exp Neurol. 2023;82:845-852.
    >> Share

    June 2023
  95. GUBBIOTTI MA, Madsen PJ, Tucker AM, Abdullaev Z, et al
    ZFTA-fused supratentorial ependymoma with a novel fusion partner, DUX4.
    J Neuropathol Exp Neurol. 2023;82:668-671.
    >> Share

  96. MAIER AD, Christiansen SN, Haslund-Vinding J, Krogager ME, et al
    DNA methylation profile of human dura and leptomeninges.
    J Neuropathol Exp Neurol. 2023;82:641-649.
    >> Share

  97. FUKUOKA K, Nakazawa A, Hirato J, Nobusawa S, et al
    An infantile pineal embryonal tumor showing pathological features of a CNS ganglioneuroblastoma and the methylation profiling of an atypical teratoid/rhabdoid tumor and SMARCA4 mutation.
    J Neuropathol Exp Neurol. 2023;82:664-667.
    >> Share

  98. BROGGI G, Barresi V
    Assessment of CDKN2A/B homozygous deletion in gliomas: To FISH or not to FISH?
    J Neuropathol Exp Neurol. 2023 Jun 12:nlad045. doi: 10.1093.
    >> Share

    May 2023
  99. LE MK, Vuong HG, Nguyen TTT, Kondo T, et al
    NAA10 overexpression dictates distinct epigenetic, genetic, and clinicopathological characteristics in adult gliomas.
    J Neuropathol Exp Neurol. 2023 May 30:nlad037. doi: 10.1093.
    >> Share

  100. LIU X, Zhao J, Wu Q, Wang L, et al
    ANKRD22 promotes glioma proliferation, migration, invasion, and epithelial-mesenchymal transition by upregulating E2F1-mediated MELK expression.
    J Neuropathol Exp Neurol. 2023 May 10:nlad034. doi: 10.1093.
    >> Share

    April 2023
  101. GUBBIOTTI MA, Dhillon KS, Harris J, Kothari S, et al
    An unusual case of metastatic diffuse midline glioma in an adult.
    J Neuropathol Exp Neurol. 2023 Apr 19:nlad032. doi: 10.1093.
    >> Share

  102. YANG X, Ye Z, Zhang M, Ouyang Y, et al
    Tissue clearing to examine glioma complexity in 3 dimensions.
    J Neuropathol Exp Neurol. 2023 Apr 6:nlad024. doi: 10.1093.
    >> Share

    March 2023
  103. PERSONS JE, Eschbacher KL
    A case of dedifferentiated meningeal solitary fibrous tumor.
    J Neuropathol Exp Neurol. 2023;82:367-369.
    >> Share

  104. CONG H, Guo X, Fan B, Liu Y, et al
    Dimethylation of histone H3 lysine 36 (H3K36me2) as a potential biomarker for glioma diagnosis, grading, and prognosis.
    J Neuropathol Exp Neurol. 2023 Mar 15:nlad016. doi: 10.1093.
    >> Share

  105. BRANDEL MG, Goodwill VS, Park A, Snyder V, et al
    Sudden unexpected death from hydrocephalus due to cerebellopontine angle meningioma.
    J Neuropathol Exp Neurol. 2023 Mar 2:nlad014. doi: 10.1093.
    >> Share

    February 2023
  106. GUBBIOTTI MA, Santi M, Storm PB, Li M, et al
    First-time identification of a KIF5B-NTRK2 fusion in extraventricular neurocytoma.
    J Neuropathol Exp Neurol. 2023;82:272-275.
    >> Share

  107. KLEINSCHMIDT-DEMASTERS BK, Ormond DR
    Leptomeningeal metastases and dural spread in adult high-grade astrocytomas.
    J Neuropathol Exp Neurol. 2023;82:194-201.
    >> Share

  108. KANG MK, Ahn SJ, Ha J, Park SH, et al
    Natural killer T-cell primary CNS lymphoma presenting as lymphomatosis cerebri: a case report and literature review.
    J Neuropathol Exp Neurol. 2023;82:261-266.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016